CEL-SCI Corp
CVM7.340USD
+0.280+3.97%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
39.06MMarket Cap
LossP/E TTM
More Details of CEL-SCI Corp Company
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
CEL-SCI Corp Info
Ticker SymbolCVM
Company nameCEL-SCI Corp
IPO dateDec 08, 1983
CEOMr. Geert R. Kersten, Esq.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endDec 08
AddressSuite 802
CityVIENNA
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code22182
Phone17035069460
Websitehttps://cel-sci.com/
Ticker SymbolCVM
IPO dateDec 08, 1983
CEOMr. Geert R. Kersten, Esq.
Company Executives of CEL-SCI Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
73.41K
+0.78%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
11.21K
+4.34%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.81K
+4.69%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
3.73K
+358.60%
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Mario Gobbo, Ph.D.
Mr. Mario Gobbo, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel H. Zimmerman, Ph.D.
Dr. Daniel H. Zimmerman, Ph.D.
Senior Vice President - Research, Cellular Immunology
Senior Vice President - Research, Cellular Immunology
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
73.41K
+0.78%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
11.21K
+4.34%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.81K
+4.69%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
3.73K
+358.60%
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Oct 23
Updated: Thu, Oct 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.94%
The Vanguard Group, Inc.
2.29%
Commonwealth Financial Network
2.19%
BlackRock Institutional Trust Company, N.A.
1.43%
Kersten (Geert R)
0.92%
Other
86.23%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.94%
The Vanguard Group, Inc.
2.29%
Commonwealth Financial Network
2.19%
BlackRock Institutional Trust Company, N.A.
1.43%
Kersten (Geert R)
0.92%
Other
86.23%
Shareholder Types
Shareholders
Proportion
Corporation
6.94%
Investment Advisor
6.69%
Individual Investor
1.26%
Investment Advisor/Hedge Fund
1.14%
Research Firm
0.54%
Other
83.43%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
122
669.31K
8.37%
+310.99K
2025Q2
130
280.62K
4.34%
-122.18K
2025Q1
141
362.72K
6.33%
+7.45K
2024Q4
154
8.90M
11.54%
-654.04K
2024Q3
159
7.92M
12.84%
-1.82M
2024Q2
170
8.27M
15.20%
-2.00M
2024Q1
223
9.54M
17.62%
-953.00K
2023Q4
231
8.54M
17.00%
-1.14M
2023Q3
241
7.38M
15.57%
-2.53M
2023Q2
252
7.44M
15.71%
-2.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
555.00K
6.94%
+555.00K
--
Aug 27, 2025
The Vanguard Group, Inc.
183.21K
2.29%
+104.78K
+133.58%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
114.25K
1.43%
+88.15K
+337.80%
Jun 30, 2025
Kersten (Geert R)
73.41K
0.92%
+570.00
+0.78%
Sep 30, 2025
MAI Capital Management, LLC
64.93K
0.81%
+47.38K
+270.01%
Jun 30, 2025
BofA Global Research (US)
40.98K
0.51%
+40.92K
+68201.67%
Jun 30, 2025
UBS Financial Services, Inc.
29.82K
0.37%
+26.88K
+914.18%
Jun 30, 2025
Geode Capital Management, L.L.C.
25.92K
0.32%
+821.00
+3.27%
Jun 30, 2025
Osaic Holdings, Inc.
15.53K
0.19%
+5.89K
+61.17%
Jun 30, 2025
View more
Related ETFs
Updated: 19 minutes ago
Updated: 19 minutes ago
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
